Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China

BACKGROUND: The burden of pneumococcal disease in China is high, and a 13-valent pneumococcal conjugate vaccine (PCV13) recently received regulatory approval and is available to Chinese infants. PCV13 protects against the most prevalent serotypes causing invasive pneumococcal disease (IPD) in China,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Shen, Kunling, Wasserman, Matthew, Liu, Dongdong, Yang, Yong-Hong, Yang, Junfeng, Guzauskas, Greg F., Wang, Bruce C. M., Hilton, Betsy, Farkouh, Raymond
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6059448/
https://ncbi.nlm.nih.gov/pubmed/30044865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0201245
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados